Document Type
Patent
Publication Date
June 2015
Patent Number
9063143
CPC
G01N 33/57449(20130101), G01N 33/57484(20130101), G01N 2800/52(20130101)
Abstract
The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
Application Number
12/975,970
Recommended Citation
Lancaster, Johnathan; Marchion, Douglas C.; and Chen, Dung-Tsa, "Cancer platinum resistance detection and sensitization method" (2015). USF Patents. 34.
https://digitalcommons.usf.edu/usf_patents/34
Assignees
University of South Florida
Filing Date
12/22/2010
